Prothena Corp Public (PRTA) Assets Average (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Assets Average of $338.3 million in Q1 2026, little changed quarter-over-quarter from $339.7 million in Q4 2025, and down 35.09% on a YoY basis from $521.2 million in Q1 2025.
Prothena Corp Public (PRTA) Assets Average (2013 - 2026) Analysis & Trends
Prothena Corp Public's Assets Average history runs 14 years deep, the most recent figure standing at $338.3 million for Q1 2026.
- In Q1 2026, Assets Average fell 35.09% year-over-year to $338.3 million; the TTM figure through Mar 2026 stood at $338.3 million (down 35.09% YoY), while the FY2025 annual figure was $437.0 million, down 29.72% from the prior year.
- Assets Average was $338.3 million for Q1 2026 at Prothena Corp Public, roughly flat from $339.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $749.8 million in Q1 2023 to a low of $338.3 million in Q1 2026.
- Historically, Assets Average has averaged $577.3 million across 5 years, with a median of $595.4 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Assets Average jumped 67.08% in 2022, then tumbled 40.52% in 2025.
- A 5-year view of Assets Average shows it stood at $656.2 million in 2022, then advanced by 9.97% to $721.7 million in 2023, then declined by 20.85% to $571.2 million in 2024, then sank by 40.52% to $339.7 million in 2025, then declined by 0.4% to $338.3 million in 2026.
- The last three Assets Average figures came in at $338.3 million (Q1 2026), $339.7 million (Q4 2025), and $375.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 26.03 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 40.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 660.38 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 338.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 338.35 Mn |
| Dec 31, 2025 | 339.72 Mn |
| Sep 30, 2025 | 375.85 Mn |
| Jun 30, 2025 | 447.20 Mn |
| Mar 31, 2025 | 521.22 Mn |
| Dec 31, 2024 | 571.18 Mn |
| Sep 30, 2024 | 620.41 Mn |
| Jun 30, 2024 | 634.38 Mn |
| Mar 31, 2024 | 659.79 Mn |
| Dec 31, 2023 | 721.65 Mn |
| Sep 30, 2023 | 733.78 Mn |
| Jun 30, 2023 | 731.12 Mn |
| Mar 31, 2023 | 749.81 Mn |
| Dec 31, 2022 | 656.24 Mn |
| Sep 30, 2022 | 552.01 Mn |
| Jun 30, 2022 | 565.50 Mn |
| Mar 31, 2022 | 595.39 Mn |
| Dec 31, 2021 | 621.04 Mn |
| Sep 30, 2021 | 534.54 Mn |
| Jun 30, 2021 | 408.05 Mn |